Current Concepts and Future Prospects for Alzheimer Disease Vaccines

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Alzheimer Disease and Associated Disorders

• Publication date

  2004-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00002093-200401000-00008PMID 15195462
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

  2003cited by this paper
• Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

  2003cited by this paper
• Progressive age-related impairment of cognitive behavior in APP23 transgenic mice.

  2003cited by this paper
• Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice

  2003cited by this paper
• Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.

  2003cited by this paper
• Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation

  2003cited by this paper
• Microglia-Mediated Nitric Oxide Cytotoxicity of T Cells Following Amyloid β-Peptide Presentation to Th1 Cells 1

  2003cited by this paper
• Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology

  2003influential reference
• Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice.

  2003cited by this paper
• Monoclonal antibodies inhibit prion replication and delay the development of prion disease

  2003cited by this paper
• Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition

  2003cited by this paper
• Slow Cognitive Decline in Alzheimer’s Disease

  2003cited by this paper
• Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease.

  2003cited by this paper
• Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

  2003cited by this paper
• Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.

  2003cited by this paper
• Anti-prion antibodies for prophylaxis following prion exposure in mice.

  2003cited by this paper
• Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning

  2002cited by this paper
• [Immunity against prions?].

  2002cited by this paper
• Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis

  2002cited by this paper
• Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

  2002cited by this paper
• Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.

  2002cited by this paper
• Immunization delays the onset of prion disease in mice.

  2002cited by this paper
• Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy

  2002cited by this paper
• Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease

  2002cited by this paper
• Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation.

  2002cited by this paper
• Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

  2002cited by this paper
• Cerebral hemorrhage after passive anti-Abeta immunotherapy.

  2002cited by this paper
• Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease

  2002cited by this paper
• Immunity against prions?

  2001cited by this paper
• Transgenic mouse models of Alzheimer's disease.

  2001cited by this paper
• Transgenic mouse models of Alzheimer's disease.

  2001cited by this paper
• Interventional strategies against prion diseases

  2001cited by this paper
• Alzheimer's disease: genes, proteins, and therapy.

  2001cited by this paper
• Behavioral Assessment of Alzheimer's Transgenic Mice Following Long-Term Aβ Vaccination: Task Specificity and Correlations between Aβ Deposition and Spatial Memory

  2001cited by this paper
• Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

  2001cited by this paper
• Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

  2001cited by this paper
• Gene conversions in genes encoding outer-membrane proteins in H. pylori and C. pneumoniae.

  2001cited by this paper
• Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy

  2001cited by this paper
• Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein Antibodies

  2001cited by this paper
• Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695*

  2001influential reference
• Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

  2000cited by this paper
• A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

  2000cited by this paper
• High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

  2000cited by this paper
• Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice.

  2000cited by this paper
• Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody.

  2000cited by this paper
• Nasal administration of amyloid‐β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease

  2000cited by this paper
• A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

  2000cited by this paper
• Inflammation and Alzheimer's disease.

  2000influential reference
• Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

  2000cited by this paper
• Nasal Aβ Treatment Induces Anti‐Aβ Antibody Production and Decreases Cerebral Amyloid Burden in PD‐APP Mice

  2000cited by this paper
• Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

  2000influential reference
• Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

  1999cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999cited by this paper
• Neuron loss in APP transgenic mice

  1998cited by this paper
• Mechanisms of cell death in Alzheimer disease--immunopathology.

  1998cited by this paper
• Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology.

  1997cited by this paper
• Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

  1997cited by this paper
• Disaggregation of Alzheimer β-amyloid by site-directed mAb

  1997cited by this paper
• Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.

  1996cited by this paper
• Inflammation and Alzheimer's disease pathogenesis.

  1996cited by this paper
• Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

  1996cited by this paper
• Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

  1995cited by this paper
• Alzheimerʼs disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein

  1988cited by this paper

• Intranasal delivery of a novel acetylcholinesterase inhibitor HLS‐3 for treatment of Alzheimer's disease

  2018cites this paper
• Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder

  2015cites this paper
• Synthesis, biological activity, and biopharmaceutical characterization of tacrine dimers as acetylcholinesterase inhibitors.

  2014cites this paper
• Immunological Aetiology of Major Psychiatric Disorders

  2012cites this paper
• Neurogenesis in Adult Hippocampus

  2012cites this paper
• Novel anti-Alzheimer’s dimer bis(7)-Cognitin: Cellular and molecular mechanisms of neuroprotection through multiple targets

  2011cites this paper
• The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease

  2011cites this paper
• Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.

  2010cites this paper
• Immunotherapy in Alzheimer's Disease: Where Do We Stand? Where Should We Go?

  2010cites this paper
• Alzheimer's Disease

  2009cites this paper
• Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?

  2009cites this paper
• Quantitation of the tacrine analogue octahydroaminoacridine in human plasma by liquid chromatography-tandem mass spectrometry.

  2009cites this paper
• An interview with Samuel Gandy, MD, PhD: Alzheimer's disease by Norman Sussman.

  2009cites this paper
• TREM2 is upregulated in amyloid plaque‐associated microglia in aged APP23 transgenic mice

  2008cites this paper
• The physicochemical properties and the in vivo AChE inhibition of two potential anti-Alzheimer agents, bis(12)-hupyridone and bis(7)-tacrine.

  2008cites this paper
• Consent in Alzheimer's Disease Research: Risk/Benefit Factors

  2007cites this paper
• Blockade of the Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Death Receptor DR5 Prevents β-Amyloid Neurotoxicity

  2007cites this paper
• The denervated hippocampus provides proper microenvironment for the survival and differentiation of neural progenitors.

  2007cites this paper
• Failed central nervous system regeneration

  2007cites this paper
• Development of a high performance liquid chromatography-tandem mass method for determination of bis(7)-tacrine, a promising anti-Alzheimer's dimer, in rat blood.

  2007cites this paper
• Over‐expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin

  2007cites this paper
• East meets West in the search for Alzheimer's therapeutics - novel dimeric inhibitors from tacrine and huperzine A.

  2007cites this paper
• Regression stage senile plaques in the natural course of Alzheimer’s disease

  2006cites this paper
• Alternatives Fehlspleißen von Tau Exon 10, Htra2-ß und Clk2 in post mortem Hirngewebe von Alzheimer-Patienten

  2005cites this paper
• Methode de prevention et de traitement de la maladie d'alzheimer

  2005cites this paper
• Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications.

  2005cites this paper
• Modulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK

  2005cites this paper
• Protein folding pathology in domestic animals

  2004cites this paper
• Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-beta vaccination in nonhuman primates.

  2004cites this paper
• Protein folding pathology in domestic animals.

  2004cites this paper
• Recent developments in prion immunotherapy.

  2004cites this paper